SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

Kelly Services is experiencing intense volatility driven by its extremely low float and active accumulation by institutional players and insiders, which has fueled widespread community speculation about a potential short squeeze. Traders are closely monitoring upcoming earnings and corporate conference calls as potential catalysts for further upward movement.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market volatility, driven by a combination of disappointing quarterly delivery figures, broader geopolitical instability in the Middle East, and active investor speculation regarding the company's valuation as a proxy for Elon Musk's wider ventures, including the upcoming SpaceX IPO. Community sentiment is deeply polarized, with traders aggressively debating whether to treat the stock as a distressed automotive manufacturer or a long-term play on AI and robotics, while many are actively using options to hedge or capitalize on the heightened price fluctuations.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing heavy volatility as traders debate the sustainability of its parabolic rally following its S&P 500 inclusion and massive AI-driven infrastructure demand. The community is sharply divided between bulls citing mission-critical optical networking bottlenecks and bears warning of a potential liquidity trap or bubble valuation.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is currently trading in a highly volatile, news-driven environment where investors are attempting to reconcile a significant spike in oil prices with a resilient equity market. Market participants remain deeply divided and cautious, with heavy debate focusing on whether the current price action is a genuine reversal or a manipulative bull trap designed to liquidate option premiums ahead of the long holiday weekend.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is rallying as the space sector gains momentum ahead of the Artemis II mission launch, with investors closely watching for impact on the broader orbital infrastructure market. The community remains highly active, debating the potential for a short squeeze while contrasting current mission optimism against lingering concerns over share offerings.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing intense volatility driven by conflicting signals between rising oil prices and algorithmic buying, leading to significant friction between bearish sentiment over geopolitical instability and bullish institutional accumulation. Community discussion is dominated by intense frustration over market manipulation, with retail traders debating whether the rapid price swings represent a sustainable rally or a deceptive trap ahead of the upcoming holiday weekend.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space (FJET) is experiencing heightened trading activity fueled by speculative interest in the broader space sector, specifically anticipation surrounding a potential SpaceX IPO and the company's recent operational updates at the Midland Air & Space Port. The stock remains a major talking point among retail investors, who are actively debating the company's long-term viability versus the potential for a volatile short squeeze given its small float and high short interest.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors position for upcoming earnings, buoyed by the integration of QNX technology into major automotive partnerships and strategic shifts toward software-defined vehicle infrastructure. Community sentiment remains polarized, with bullish long-term investors highlighting the growing royalty backlog and safety-critical moat as catalysts for a potential reversal, while skeptics remain focused on past revenue performance and management guidance.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing significant investor interest driven by strong Q4 earnings, reduced debt, and a strategic pivot toward domestic pharmaceutical manufacturing and advanced materials. The community is actively discussing the stock's potential for a "short squeeze" and speculating on upcoming regulatory catalysts, while debating the company's valuation as it works to solidify its role in the U.S. supply chain.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors monitor the early commercial launch of its FDA-approved therapy YARTEMLEA and await updates on potential milestone payments from its partnership with Novo Nordisk. Community discussion is heavily focused on the stock's undervaluation relative to its pipeline potential, the impact of significant short interest, and optimism surrounding upcoming European regulatory decisions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.05. The business had revenue of $1.05 million for the quarter, compared to...

Arbutus Biopharma (ABUS) Projected to Post Quarterly Earnings on Thursday

Arbutus Biopharma (NASDAQ:ABUS) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-arbutus-biopharma-co-stock...

Foursixthree Capital LP Has $8.99 Million Stake in Arbutus Biopharma Corporation $ABUS

Foursixthree Capital LP decreased its holdings in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) by 22.6% during the 3rd quarter, according to the company in its most recent Form...

Arbutus Biopharma (NASDAQ:ABUS) Shares Down 8.4% - Time to Sell?

Arbutus Biopharma (NASDAQ:ABUS) Trading Down 8.4% - What's Next...

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average - Here's Why

Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened...

<ul class="summary-bullets"><li>Citi kept a ‘Neutral’ rating on Moderna with a $41 price target.</li><li>BofA contends that Moderna's settlement takes "a meaningful chunk of the litigation overhang off the table," but adds that the agreement is "also not the walk-away outcome we expect some bulls were hoping for."&nbsp;</li><li>Under the settlement, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026.</li></ul><p>Shares of vaccine maker Moderna (MRNA) rallied 16% on Wednesday after the company announced that it has entered into an up to $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma over a vaccine patent row which has left analysts divided.</p><p>Under the <a href="https://stocktwits.com/news-articles/markets/equity/mrna-shares-rally-after-hours-on-settlement-deal-over-vaccine-patent-row/cZderPnRIPy">settlement</a>, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026. The remaining $1.3 billion is subject to further litigation, the company said on Tuesday. If Moderna prevails in the litigation, no further payments will be due but if it doesn't, it will have to make an additional payment of up to $1.3 billion.</p><h2 class="st-heading-2">Analyst Take</h2><p>Citi analyst Geoff Meacham views Moderna's settlement with Arbutus as not the best-case scenario of an outright win but better than feared. The news is likely to come as a relief to many investors, the analyst told investors in a research note, while adding that it thinks the settlement removes an overhang for the stock. Citi kept a ‘Neutral’ rating on Moderna with a $41 price target.</p><p>BofA, likewise, contends that Moderna's settlement takes "a meaningful chunk of the litigation overhang off the table," but adds that the agreement is "also not the walk-away outcome we expect some bulls were hoping for."</p><p>The structure leaves "a contingent tail" as Moderna could owe an additional payment of up to $1.3 billion if further litigation affirms liability, noted the analyst, who reiterated an ‘Underperform’ rating and $31 price target on Moderna shares.</p><h2 class="st-heading-2">Settlement Deal</h2><p>The settlement announced on Tuesday resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ Lipid Nanoparticle (LNP) delivery technology in its COVID-19 vaccine Spikevax as well as respiratory syncytial virus (RSV) vaccine mRESVIA. The company said that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around MRNA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained nearly 90% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/farm-stock-sinks-to-48-year-lows-what-triggered-the-collapse/cZd9tBARId3">FARM Stock Sinks To 48-Year Lows – What Triggered The Collapse?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock

The news is likely to come as a relief to many investors, Citi told investors in a research note. 

Equity

The news is likely to come as a relief to many investors, Citi told investors in a research note. 


Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading Volume - What's Next?

Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading Volume - Still a Buy...

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.

Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus

(RTTNews) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary of Roivant...

<ul class="summary-bullets"><li>Moderna said that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.&nbsp;</li><li>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026.</li><li>The remaining $1.3 billion payout is subject to further litigation.</li></ul><p>Shares of vaccine maker Moderna (MRNA) rallied after hours on Tuesday after the company announced that it has entered into an up to $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma.</p><p>The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ Lipid Nanoparticle (LNP) delivery technology in its COVID-19 vaccine Spikevax as well as respiratory syncytial virus (RSV) vaccine mRESVIA. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5178901572623640&amp;symbol=MRNA">said</a> that the settlement provides certainty going forward for the company’s entire infectious disease portfolio and its future vaccine pipeline with no future royalties owed.</p><p><a href="https://stocktwits.com/symbol/ABUS">Shares of Arbutus</a> fell 8% after hours at the time of writing while shares of Genevant’s parent <a href="https://stocktwits.com/symbol/ROIV">Roivant Sciences</a> gained nearly 1%. Meanwhile, shares of MRNA rallied 11%.</p><h2 class="st-heading-2">Settlement Agreement</h2><p>Under the deal, Moderna will pay Arbutus and Genevant $950 million in the third quarter of 2026. The remaining $1.3 billion is subject to further litigation. If Moderna prevails in the litigation, no further payments will be due but if it doesn't, it will have to make an additional payment of up to $1.3 billion.</p><p>"Resolving this legacy matter from our pandemic response removes uncertainty and allows us to turn our full focus to Moderna's exciting near-term future," said Moderna CEO Stéphane Bancel.</p><p>The company now expects to end the year with $4.5 to $5.0 billion in cash and cash equivalents. The total projected liquidity available to the company at the end of 2026 will be $5.4 to $5.9 billion, it added.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around MRNA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained nearly 65% over the past 12 months. Meanwhile, ABUS and ROIV added 37% and 174%, respectively.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/autozone-shares-dive-post-earnings-but-wells-fargo-sees-buying-opportunity/cZdeYkuRIPt">AutoZone Shares Dive Post-Earnings But Wells Fargo Sees A Buying Opportunity</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccine Spikevax.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Current Price	$4.46
Prev Close	$4.52
Open	$4.38
Dividend Yield	0.00%
50-Day Moving Average	$4.32
Beta	0.96
Avg. Volume	3.1M
PE Ratio	-25.77

52-Week High	$5.10
52-Week Low	$2.71
Market Capitalization	$883.56M
EPS (Annual)	-$0.1748
Price to Book	11.36
Revenue Per Employee	$741,210.53

ABUS
Arbutus Biopharma Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABUS News

ABUSArbutus Biopharma Corp